Background: Alpha-2-antiplasmin (α2AP) is the main natural inhibitor of plasmin. The C-terminus of α2AP is crucial for the initial interaction with plasmin(ogen) and the rapid inhibitory mechanism. Approximately 35% of circulating α2AP has lost its C-terminus (non-plasminogen binding α2AP/NPB-α2AP) and thereby its rapid inhibitory capacity.
| INTRODUC TI ON
Alpha-2-antiplasmin (α2AP) is the main natural inhibitor of the fibrinolytic enzyme plasmin. [1] [2] [3] Native α2AP is produced by the liver and circulates in blood as an approximately 67-kDa single-chain glycoprotein of 464 amino acid residues, containing 11% to 14% carbohydrate. 2, 4, 5 α2AP possesses unique N-and C-terminal ends, as we extensively reviewed. 6 The N-terminus is involved in α2AP incorporation into a blood clot by activated factor XIII-mediated crosslinking. 7, 8 The C-terminus is crucial for the initial interaction of α2AP with plasmin(ogen). 9 α2AP contains six lysine residues at its C-terminus, which are involved in the interaction with lysine binding sites in plasminogen. 9, 10 Based on the interaction with these lysine binding sites, two molecular species of α2AP have been described in plasma. 11 One molecular form is able to bind to plasminogen (plasminogen binding α2AP, PB-α2AP), comprises approximately 65% of circulating α2AP, and is a fast-acting inhibitor of plasmin by rapidly forming plasmin-antiplasmin complexes. The other molecular form, which comprises approximately 35% of circulating α2AP, does not bind to plasminogen (non-plasminogen binding α2AP, NPB-α2AP) and inhibits plasmin at a much slower rate. 11, 12 Kluft and Los demonstrated the presence of the two variants in plasma and in serum by modified crossed immunoelectrophoresis. 13 They also showed that only PB-α2AP is produced in the liver and that NPB-α2AP is the result of posttranslational modification in the circulation. 14 Furthermore, it was reported that the NPB-α2AP fraction in plasma may contain some inactive or inactivated inhibitor. 11, 15 In addition to the main form of NPB-α2AP in vivo, it was shown that purified PB-α2AP can spontaneously convert into an NPB-α2AP form in vitro. 16 Sasaki et al 17 treated both purified PB-α2AP and in vitro formed NPB-α2AP after acetamidination with trypsin and analyzed the peptides by HPLC. A peptide representing the 26 C-terminal amino acids of the molecule was found in PB-α2AP, which was not present in NPB-α2AP formed in vitro. This indicated the participation of this C-terminal part in plasminogen binding. Some subsequent papers have mistakenly considered this trypsin cleavage site as the position where PB-α2AP is truncated into NPB-α2AP. 18, 19 The study by Sasaki et al only showed that NPB-α2AP is formed in vitro after a cleavage of a peptide smaller than 26 amino acid residues. To date, it is unknown where and how the conversion happens in the circulation. An actual in vivo cleavage site and a protease responsible have not yet been identified.
Leebeek et al 20 have suggested that the in vivo and in vitro conversions of PB-α2AP to NPB-α2AP in plasma may have different mechanisms and possibly involve different cleavage sites. Using a commercially available monoclonal antibody against the C-terminus of α2AP (TC 3AP 21 ) in a crossed immunoelectrophoresis technique, they showed that NPB-α2AP formed in vivo lost its capacity to bind to both plasminogen and the antibody, whereas NPB-α2AP formed in vitro lost the plasminogen binding capacity, but could still bind to the antibody. This indicated that in vivo and in vitro generated NPB-α2AP are not the same molecules but may differ in their C termini or may be structurally different. We reckoned that the epitope recognized by TC 3AP in the α2AP protein can be used to obtain a crude localization of the in vivo C-terminal cleavage site of α2AP; therefore, this study aimed to determine the epitope of TC 3AP and subsequently localize the C-terminal cleavage site of α2AP by mass spectrometry.
| ME THODS

| Materials
Pooled normal plasma was prepared from citrated apheresis plasma (Sanquin blood bank, Rotterdam, The Netherlands) of five healthy donors. Commercially available plasma-purified α2AP (Calbiochem) was purchased from Merck Millipore. The mouse monoclonal antibody against the C-terminus of α2AP (TC 3AP) was purchased from Technoclone. The custom made polyclonal rabbit Asn-α2AP antibody (anti-Asn-α2AP, affinity purified IgG) was raised against a peptide corresponding to amino acids Gln14 to Pro30 of the α2AP protein (Charles River Laboratories, Squarix GmbH) and has been used previously. 22 The polyclonal goat total α2AP antibody (affinity purified IgG) (anti-total α2AP) directed to all forms of α2AP and the horseradish peroxidase-conjugated anti-total α2AP antibody were purchased from Affinity Biologicals. Cyanogen bromide-activated-Sepharose ® 4B was purchased from GE Healthcare. SigmaFAST TM Protease Inhibitor Cocktail, ammonium bicarbonate, 2-chloroacetamide, 1,4-dithiothreitol (DTT), and 3,3′,5,5′-tetramethylbenzidine were purchased from Sigma-Aldrich. Magnetic Dynabeads® Protein G, GelCode® Blue Stain Reagent, and endoproteinase Glu-C were purchased from Thermo Fisher Scientific. Endoproteinase Arg-C was purchased from Protea. Endoproteinase Asp-N was obtained from Roche. Endoproteinase Lys-N was purchased from U-Protein Express BV. XT Sample Buffer, XT reducing agent, and precast XT Criterion 10% polyacrylamide gels were purchased from BioRad.
| Epitope mapping of antibody TC 3AP
Epitope mapping of TC 3AP was carried out according to an adapted epitope extraction method as described previously. 23, 24 In detail, commercially available plasma-purified α2AP, lyophilized in buffer (200 mmol/L NaCl, 20 mmol/L Bis-Tris, pH 6.4), was resuspended in Essentials • Due to proteolytic cleavage, part of circulating a2-antiplasmin (α2AP) loses the C-terminus.
• C-terminally cleaved α2AP is unable to inhibit plasmin rapidly.
• We found that C-terminal cleavage of α2AP occurs between residues Leu417 and Asp422.
• Our study gives more insight into the regulation of C-terminal heterogeneity of α2AP. 
| Purification of α2AP
For the localization of the C-terminal cleavage site, PB-and NPB-α2AP were purified from normal pooled plasma by affinity chromatography. Briefly, 1 mg anti-total α2AP was coupled to 1 mL cyanogen bromide-activated-Sepharose ® 4B. Normal pooled plasma The eluted fractions with the highest α2AP concentrations were pooled and dialyzed against distilled water. Finally, the dialyzed pooled sample was dried by a SpeedVac procedure and resuspended in 60 µL distilled water.
| SDS-PAGE and Western blotting
To separate PB-α2AP and NPB-α2AP, 5 µg (for SDS-PAGE) and 300 ng (for Western blot analyses) affinity-purified α2AP in Notes: Dev, the difference between the observed and calculated mass (in ppm); frequency, the number of times a peptide is observed in the mass spectrometry analysis; mass: the theoretical monoisotopic mass of the neutral peptide (in Daltons); m/z, the observed mass/charge; score, the ions score given to the peptide.
TA B L E 1 Epitope mapping of antibody TC 3AP
Peptides identified by Mascot analysis in the immobilized TC 3AP-bound α2AP fraction produced by enzymatic digestion of α2AP with Asp-N. Best scoring spectra are reported. (Table S1 ). Numbering of α2AP amino acids was according to methionine in position 1.
| Mass spectrometry for epitope mapping and C-terminal cleavage site analysis
| RE SULTS
| Epitope mapping of antibody TC 3AP
To obtain a crude localization of the α2AP C-terminal cleavage site, we first determined the epitope of TC 3AP. Because this antibody does not react with NPB-α2AP, we hypothesized that the in vivo cleavage site is located N-terminally from the TC 3AP epitope. The MS data of the Asp-N digest identified two peptides that were bound to immobilized TC 3AP and that should contain the epitope of TC 3AP: Asp428-Gly439 (ions score: 39 and 51) and Asp422-Gly439 (ions score: 41, 57 and 61) ( Table 1) . Multiple ions scores were found for the same peptide, depending on their charge (2+, 3+, or 4+). The MS data of the Glu-C and Lys-N digests did not display any peptides, probably because of the presence of multiple protease specific cleavage sites in this region, resulting in small peptides that do not bind to immobilized TC 3AP or are undetectable by MS. Thus, we localized the epitope of TC 3AP to the region between Asp428 and Gly439.
| C-terminal cleavage site analysis
SDS-PAGE of the affinity purified α2AP showed protein bands with molecular weights between 50 and 67 kDa ( Figure 1A) . Western blot analyses showed reactivity of the anti-Asn-α2AP antibody to apparently two bands with molecular weights of approximately 60 kDa and 67 kDa ( Figure 1B) . Multiple protein bands within the 60-to 67-kDa range showed reactivity with TC 3AP (Figure 1C ), indicating the presence of the C-terminus. However, there was one protein band at approximately 63 kDa that did not react with TC 3AP, suggesting the absence of the C-terminus, thus representing NPB-α2AP (red band in Figure 1D ). The two minor bands below the main band of PB-α2AP
in Figure 1C 
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Notes: Dev, the difference between the observed and calculated mass (in ppm); frequency, the number of times a peptide is observed in the mass spectrometry analysis; mass: the theoretical monoisotopic mass of the neutral peptide (in Daltons); m/z, the observed mass/charge; n.d., not determined; score, the ions score given to the peptide.
Best scoring spectra are reported. a Deamidation.
Mascot analysis data from the pilot experiment with Arg-C displayed one peptide (Asn408-Gln421) in the NPB-α2AP protein band that did not end with the Arg-C specific amino acid residue arginine (data not shown). This peptide was not present in PB-α2AP.
Therefore, we hypothesized that this C-terminal end was already present in the purified α2AP sample and represents the in vivo cleavage site. The digestions with Asp-N, Lys-C, and trypsin did not result in any C-terminal ends that were not the result of protease specific cleavages. The experiment with Arg-C digestion of NPB-α2AP was repeated under optimized conditions to confirm the Gln421-Asp422 cleavage site. Mascot analysis data identified six peptides that could not be ascribed to the action of Arg-C: Asn408-Leu417, Asn408-Glu419, Asn408-Gln420, Asn408-Gln421, deamidated Asn408-Gln421, and Asn408-Asp422 (Table 2) . MaxQuant analysis data from the optimized experiment revealed four of these six peptides: Asn408-Gln420, Asn408-Gln421, deamidated Asn408-Gln421, and Asn408-Asp422 (Table 2 ; Figures S1-S6) . In both analysis methods, the Asn408-Gln421 peptide displayed the highest ions scores and best spectra ( Figure 2 ). Therefore, our data suggest that the Gln421-Asp422 is a preferred cleavage site in the C-terminus of α2AP.
Taken together, our results suggest that in vivo NPB-α2AP results from cleavage after Leu417, Glu419, Gln420, Gln421, or Asp422, with Gln421 as preferred cleavage site ( Figure 3 ). As expected, the Leu417-Asp422 region is located N-terminally from the TC 3AP epitope, explaining why NPB-α2AP is not detected by TC 3AP, as summarized in Figure 4 .
| D ISCUSS I ON
In this study, we determined the epitope of monoclonal antibody TC 3AP, which detects PB-α2AP but not in vivo formed NPB-α2AP. 20 Supported by this information, we specified where PB-α2AP is truncated in vivo for the generation of NPB-α2AP. We found that the TC 3AP epitope is located in a region between Asp428 and Gly439 We found that in vivo cleavage of PB-α2AP occurs between Leu417 and Asp422. In a previous study, Clemmensen et al described the purification of PB-α2AP from plasma. 16 In that study, PB-α2AP (67 kDa) was spontaneously converted in vitro into two different forms with lower molecular weights (65 and 60 kDa). Native PB-α2AP was able to bind plasminogen and rapidly inactivate plasmin, whereas the 65-kDa form did not bind plasminogen but could still slowly inactivate plasmin. The 60-kDa form neither bound plasminogen nor inactivated plasmin. In our study, we focused on in vivo-generated NPB-α2AP. This NPB-α2AP form still contains the reactive site, which is needed for plasmin inhibition. Our MS data revealed several possible C-terminal cleavage sites, located C-terminally from the reactive site, indicating that the NPB-α2AP form still has inhibitory activity toward plasmin. Thus, although Sasaki et al showed that in vitro-generated 65 kDa NPB-α2AP lacks at most 26 amino acid residues (cleavage after Arg438), 17 our MS data show that in vivogenerated NPB-α2AP lacks about 43 amino acid residues by cleavage in a region between Leu417 and Asp422.
Leebeek et al 20 described that NPB-α2AP formed in vivo lost its capacity to bind to both plasminogen and TC 3AP, which is in line with our MS data showing that NPB-α2AP formed in vivo is cleaved in a region between Leu417 and Asp422, which is located N-terminally from the TC 3AP epitope. Furthermore, they showed that NPB-α2AP formed in vitro lost its plasminogen binding capacity, but could still bind to TC 3AP. 20 This in vitro-formed NPB-α2AP might be similar to the 65-kDa form of NPB-α2AP described by Sasaki et al, 17 which lacks at most 26 amino acid residues (Gly439-Lys464), and still contains the TC 3AP epitope located in a region between Asp428 and Gly439.
Five potential cleavage sites located in close proximity of each other were obtained from MS data, indicating the possibility of multiple NPB-α2AP forms and suggesting the presence of a proteolytic sensitive region (Figure 4 ). This makes the possibility of NPB-α2AP being the result of cleavage by one specific regulating protease unlikely. However, the highest ions scores and best spectra were found for the Asn408-Gln421 peptide. This peptide was also prominently found in the pilot experiment, suggesting that the Gln421-Asp422 is a preferred cleavage site. The Peptidase Database MEROPS (release 12.1) contains 33 enzymes capable of cleaving Gln-Asp bonds and might be helpful for finding candidate enzymes.
An alternative explanation for the five potential cleavage sites is that PB-α2AP is cleaved by one endopeptidase at Asp422-Ser423 and further truncated by different carboxypeptidases, such as thrombin-activatable fibrinolysis inhibitor and carboxypeptidase N. It is, however, unknown whether all required carboxypeptidases exist in plasma. Mutagenesis of α2AP could be useful to further study the cleavage region.
To date, there is no three-dimensional protein structure available for the complete C-terminus of α2AP, because of its flexibility. 26 Law et al 26 showed that the first 10 amino acids of the C-terminus of α2AP (Asn410-Glu419) are tightly associated with the serpin body, because residues 416 and 417 are incorporated in β-sheet C. The remainder of the C-terminus (Gln420-Lys464) could not be modeled into electron density. The C-terminal cleavage sites described in the current study are situated between Leu417 and Asp422, which are located in the beginning of the flexible C-terminus ( Figure 3 ). Therefore, it is plausible that the found C-terminal cleavage sites are located in a region sensitive for proteolysis.
To conclude, we mapped the epitope of antibody TC 3AP and localized the in vivo C-terminal cleavage sites of PB-α2AP. These results can be used to gain more insight into the regulation of C-terminal heterogeneity of α2AP and thus the regulation of the fi- 
